JPWO2022258015A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022258015A5 JPWO2022258015A5 JP2023575788A JP2023575788A JPWO2022258015A5 JP WO2022258015 A5 JPWO2022258015 A5 JP WO2022258015A5 JP 2023575788 A JP2023575788 A JP 2023575788A JP 2023575788 A JP2023575788 A JP 2023575788A JP WO2022258015 A5 JPWO2022258015 A5 JP WO2022258015A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- cdr
- seq
- antigen
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/099228 | 2021-06-09 | ||
| CN2021099228 | 2021-06-09 | ||
| PCT/CN2022/097889 WO2022258015A1 (en) | 2021-06-09 | 2022-06-09 | Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024523838A JP2024523838A (ja) | 2024-07-02 |
| JP2024523838A5 JP2024523838A5 (https=) | 2025-06-18 |
| JPWO2022258015A5 true JPWO2022258015A5 (https=) | 2025-06-18 |
Family
ID=84425689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575788A Pending JP2024523838A (ja) | 2021-06-09 | 2022-06-09 | Ｏｘ４０及び／又はｐｄ－ｌ１に結合する抗体及び二重特異性結合タンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250282881A1 (https=) |
| EP (1) | EP4352108A4 (https=) |
| JP (1) | JP2024523838A (https=) |
| KR (1) | KR20240019797A (https=) |
| CN (1) | CN117529503A (https=) |
| AU (1) | AU2022288037A1 (https=) |
| CA (1) | CA3221866A1 (https=) |
| IL (1) | IL308918A (https=) |
| TW (1) | TW202315893A (https=) |
| WO (1) | WO2022258015A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116970059A (zh) * | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| CN110337448B (zh) * | 2016-12-23 | 2023-08-08 | 瑞美德生物医药科技有限公司 | 使用与程序性死亡配体1(pd-l1)结合的抗体的免疫疗法 |
| SG11201912865VA (en) * | 2017-06-25 | 2020-01-30 | Systimmune Inc | Multi-specific antibodies and methods of making and using thereof |
| WO2019094574A1 (en) * | 2017-11-09 | 2019-05-16 | Medimmune, Llc | Bispecific fusion polypeptides and methods of use thereof |
| CN118047873A (zh) * | 2017-12-29 | 2024-05-17 | 圆祥生技股份有限公司 | 调节免疫检查点作为癌症治疗的单特异性蛋白质 |
| CN110305210B (zh) * | 2018-03-27 | 2023-02-28 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
| CN112739717B (zh) * | 2018-06-29 | 2025-02-11 | 璟尚生物制药公司 | 三特异性拮抗剂 |
| CN119798453A (zh) * | 2018-11-13 | 2025-04-11 | Jn生物科学有限责任公司 | 激活免疫细胞的双特异性抗体 |
| US10442866B1 (en) * | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
| TWI793395B (zh) * | 2019-01-25 | 2023-02-21 | 大陸商信達生物製藥（蘇州）有限公司 | 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體 |
| CN110003338B (zh) * | 2019-04-16 | 2021-04-23 | 北京免疫方舟医药科技有限公司 | 抗ox40抗体及其应用 |
| WO2021104434A1 (en) * | 2019-11-27 | 2021-06-03 | Shanghai Epimab Biotherapeutics Co., Ltd. | TGFβ/PD-L1 BISPECIFIC BINDING PROTEINS |
-
2022
- 2022-06-09 JP JP2023575788A patent/JP2024523838A/ja active Pending
- 2022-06-09 KR KR1020247000219A patent/KR20240019797A/ko active Pending
- 2022-06-09 TW TW111121529A patent/TW202315893A/zh unknown
- 2022-06-09 AU AU2022288037A patent/AU2022288037A1/en active Pending
- 2022-06-09 EP EP22819612.7A patent/EP4352108A4/en active Pending
- 2022-06-09 CA CA3221866A patent/CA3221866A1/en active Pending
- 2022-06-09 IL IL308918A patent/IL308918A/en unknown
- 2022-06-09 WO PCT/CN2022/097889 patent/WO2022258015A1/en not_active Ceased
- 2022-06-09 US US18/568,252 patent/US20250282881A1/en active Pending
- 2022-06-09 CN CN202280040981.5A patent/CN117529503A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109983033B (zh) | 调节细胞表达的生物活性的结合分子 | |
| CN109641049B (zh) | Cd3结合抗体 | |
| US11746148B2 (en) | Antibody molecules comprising a single-domain antigen-binding site and Fab fragments | |
| AU2018233976B2 (en) | Fc-optimized anti-CD25 for tumour specific cell depletion | |
| JP6873901B2 (ja) | Ｔｎｆファミリーリガンド三量体を含む抗原結合分子 | |
| AU2016257334B2 (en) | Combination of a CD30xCD16 antibody with a PD-1 antagonist for therapy | |
| JP7489468B2 (ja) | 二重特異性融合タンパク質及びその応用 | |
| WO2021063330A1 (zh) | 靶向cd3的抗体、双特异性抗体及其用途 | |
| TW202430563A (zh) | 抗cd38抗體及其使用方法 | |
| JP2020522495A (ja) | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 | |
| AU2020363041B2 (en) | Antibodies against the poliovirus receptor (PVR) and uses thereof | |
| JP2020525517A (ja) | 腫瘍特異的細胞枯渇のための化合物及び方法 | |
| WO2022258015A1 (en) | Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1 | |
| CN115260312A (zh) | 结合ox40的抗体或抗原结合片段 | |
| JPWO2022258015A5 (https=) | ||
| WO2024085166A1 (ja) | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 | |
| CN119894930A (zh) | 一种双特异性抗体及其应用 | |
| RU2805648C2 (ru) | Биспецифические связывающие молекулы, способные связывать cd137 и опухолевые антигены, и варианты их применения | |
| Guelen et al. | Wong | |
| HK40082471A (en) | Binding protein having h2l2 and hcab structures | |
| JP2025530110A (ja) | 二重特異性ポリペプチド及びその使用 | |
| CN116323658A (zh) | 靶向PD-1或PD-L1和TGF-β的双功能蛋白及其医药用途 | |
| EA051900B1 (ru) | Антитела против cd112r и варианты их применения | |
| EA045980B1 (ru) | Антитела против рецептора полиовируса (pvr) и их применение | |
| HK40016585A (en) | Fc-optimized anti-cd25 for tumor specific cell depletion |